%0 Journal Article %J Science Immunology %D 2022 %T An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion %A Sai Luo %A Zhang, Jun %A Alex J.B. Kreutzberger %A Amanda Eaton %A Robert J. Edwards %A Changbin Jing %A Hai-Qiang Dai %A Gregory D. Sempowski %A Kenneth Cronin %A Robert Parks %A Ye, Adam Yongxin %A Katayoun Mansouri %A Maggie Barr %A Pishesha, Novalia %A Aimee Chapdelaine Williams %A Lucas Vieira Francisco %A Anand Saminathan %A Peng, Hanqin %A Himanshu Batra %A Lorenza Bellusci %A Surender Khurana %A S. Munir Alam %A David C. Montefiori %A Kevin O. Saunders %A Tian, Ming %A Ploegh, Hidde %A Tom Kirchhausen %A Chen, Bing %A Barton F. Haynes %A Frederick W. Alt %X SARS-CoV-2 Omicron sub-variants have generated a world-wide health crisis due to resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of vaccination-induced antibodies. To manage Omicron sub-variants and prepare for potential new variants, additional means of isolating broad and potent humanized SARS-CoV-2-neutralizing antibodies are desirable. Here, we describe a mouse model in which the primary B cell receptor (BCR) repertoire is generated solely through V(D)J recombination of a human VH1-2 heavy chain (HC) and, substantially, a human Vκ1-33 light chain (LC). Thus, primary humanized BCR repertoire diversity in these mice derives from immensely diverse HC and LC antigen-contact complementarity-region-3 (CDR3) sequences generated by non-templated junctional modifications during V(D)J recombination. Immunizing the human VH1-2/Vκ1-33-rearranging mouse model with SARS-CoV-2 (Wuhan-Hu-1) spike protein immunogens elicited several VH1-2/Vκ1-33-based neutralizing antibodies that bound RBD in a different mode from each other and from those of many prior human patient-derived VH1-2-based neutralizing antibodies. Of these, SP1-77 potently and broadly neutralized all SARS-CoV-2 variants through BA.5. Cryo-EM studies revealed that SP1-77 bound RBD away from the receptor-binding-motif via a CDR3-dominated recognition mode. Lattice-light-sheet-microscopy-based studies showed that SP1-77 did not block ACE2-mediated viral attachment or endocytosis, but rather blocked viral-host membrane fusion. The broad and potent SP1-77 neutralization activity and non-traditonal mechanism of action suggest this antibody might have therapeutic potential. Likewise, the SP1-77 binding epitope may further inform on vacccine strategies. Finally, the general class of humanized mouse models we have described may contribute to identifying therapeutic antibodies against future SARS-CoV-2 variants and other pathogens. A humanized antibody from a recently-developed mouse model potently neutralizes SARS-CoV-2 variants by inhibiting membrane fusion. %B Science Immunology %P eadd5446 %G eng %U https://www.science.org/doi/abs/10.1126/sciimmunol.add5446 %R 10.1126/sciimmunol.add5446